Addition of lomustine to idarubicin and cytarabine improves the outcome of elderly patients with de novo acute myeloid leukemia: A report from the GOELAMS

Journal of Clinical Oncology

Volumn 28, Issue 18, 2010, Pages 3028-3034

  Pigneux, Arnaud ^a   Harousseau, Jean Luc ^a   Witz, Francis ^a   Sauvezie, Mathieu ^a   Bene, Marie Christine ^a   Luquet, Isabelle ^a   Hunault Berger, Mathilde ^a   Recher, Christian ^a   Lioure, Bruno ^a   Himberlin, Chantal ^a   Escoffre Barbe, Martine ^a   Berthou, Christian ^a   Lissandre, Severine ^a   Fegueux, Nathalie ^a   Cahn, Jean Yves ^a   Jourdan, Eric ^a   Dreyfus, François ^a   Reiffers, Josy ^a   Milpied, Noël ^a   Ifrah, Norbert ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CYTARABINE; FLUDARABINE; IDARUBICIN; LOMUSTINE; ANTINEOPLASTIC AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED STUDY; CYTOGENETICS; ELDERLY CARE; FEMALE; HUMAN; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NAUSEA; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME; COHORT ANALYSIS; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; REMISSION; RETROSPECTIVE STUDY; SURVIVAL RATE;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COHORT STUDIES; CYTARABINE; FEMALE; HUMANS; IDARUBICIN; LEUKEMIA, MYELOID, ACUTE; LOMUSTINE; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 77954569395     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.26.4648     Document Type: Article

References (30)

1. Estey E, Dohner H: Acute myeloid leukaemia. Lancet 368:1894-1907, 2006
2. Anderson JE, Kopecky KJ, Willman CL, et al: Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: A Southwest Oncology Group study. Blood 100:3869-3876, 2002 (Pubitemid 35396851)
3. Goldstone AH, Burnett AK, Wheatley K, et al: Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: The results of the United Kingdom Medical Research Council AML11 trial. Blood 98:1302-1311, 2001
4. Hiddemann W, Kern W, Schoch C, et al: Management of acute myeloid leukemia in elderly patients. J Clin Oncol 17:3569-3576, 1999 (Pubitemid 29517929)
5. Lowenberg B, Suciu S, Archimbaud E, et al: Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy-the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: Final report: European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group. J Clin Oncol 16:872-881, 1998 (Pubitemid 28115455)
6. Reiffers J, Huguet F, Stoppa AM, et al: A prospective randomized trial of idarubicin vs daunorubicin in combination chemotherapy for acute myelogenous leukemia of the age group 55 to 75. Leukemia 10:389-395, 1996 (Pubitemid 26128775)
7. Stone RM, Berg DT, George SL, et al: Postremission therapy in older patients with de novo acute myeloid leukemia: A randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine. Blood 98:548-553, 2001
8. Appelbaum FR, Gundacker H, Head DR, et al: Age and acute myeloid leukemia. Blood 107:3481-3485, 2006
9. Frohling S, Schlenk RF, Kayser S, et al: Cyto-genetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: Results from AMLSG trial AML HD98-B. Blood 108:3280-3288, 2006
10. Leith CP, Kopecky KJ, Chen IM, et al: Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/Pglycoprotein, MRP1, and LRP in acute myeloid leukemia: A Southwest Oncology Group Study. Blood 94:1086-1099, 1999
11. Raspadori D, Damiani D, Michieli M, et al: CD56 and PGP expression in acute myeloid leukemia: Impact on clinical outcome. Haematologica 87:1135-1140, 2002 (Pubitemid 35397771)
12. Ryan DH, Kopecky KJ, Head D, et al: Analysis of treatment failure in acute nonlymphocytic leukemia patients over fifty years of age: A Southwest Oncology Group study. Am J Clin Oncol 15:69-75, 1992
13. Brajtburg J, Elberg S, Schechtman KB, et al: Lysis of human promyelocytic HL-60 cells by amphotericin B in combination with 2-chloroethyl-1- nitrosoureas: Role of the carbamoylating activity of nitrosoureas. Cancer Res 50:3274-3278, 1990 (Pubitemid 20190130)
14. Gerson SL, Trey JE: Modulation of nitrosourea resistance in myeloid leukemias. Blood 71:1487-1494, 1988
15. Gerson SL, Trey JE, Miller K: Potentiation of nitrosourea cytotoxicity in human leukemic cells by inactivation of O6-alkylguanine-DNA alkyltransferase. Cancer Res 48:1521-1527, 1988 (Pubitemid 18091200)
16. Oksenhendler E, Landais P, Cordonnier C, et al: Acral erythema and systemic toxicity related to CHA induction therapy in acute myeloid leukemia. Eur J Cancer Clin Oncol 25:1181-1185, 1989 (Pubitemid 19209612)
17. Pigneux A, Perreau V, Jourdan E, et al: Adding lomustine to idarubicin and cytarabine for induction chemotherapy in older patients with acute myeloid leukemia: The BGMT 95 trial results. Haematologica 92:1327-1334, 2007 (Pubitemid 350153468)
18. Giles F, Rizzieri D, Karp J, et al: Cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients age 60 years or older with previously untreated acute myeloid leukemia. J Clin Oncol 25:25-31, 2007 (Pubitemid 350003047)
19. Pigneux A: Laromustine, a sulfonyl hydrolyzing alkylating prodrug for cancer therapy. IDrugs 12:39-53, 2009
20. Bennett JM, Catovsky D, Daniel MT, et al: Proposed revised criteria for the classification of acute myeloid leukemia: A report of the French- American-British Cooperative Group. Ann Intern Med 103:620-625, 1985
21. Reference deleted
22. Cheson BD, Bennett JM, Kopecky KJ, et al: Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 21:4642-4649, 2003 (Pubitemid 46594039)
23. Peto R, Pike MC, Armitage P, et al: Design and analysis of randomized clinical trials requiring prolonged observation of each patient: II. Analysis and examples. Br J Cancer 35:1-39, 1977 (Pubitemid 8018922)
24. Baer MR, George SL, Caligiuri MA, et al: Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720. J Clin Oncol 26:4934-4939, 2008
25. Burnett AK, Milligan D, Goldstone A, et al: The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: The results of the LRF AML14 trial. Br J Haematol 145:318-332, 2009
26. Gardin C, Turlure P, Fagot T, et al: Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: Results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial. Blood 109:5129-5135, 2007 (Pubitemid 46900774)
27. Martin MG, Abboud CN: Induction therapy for elderly patients with acute myeloid leukemia. Blood Rev 22:311-320, 2008
28. Preisler H, Davis RB, Kirshner J, et al: Comparison of three remission induction regimens and two postinduction strategies for the treatment of acute nonlymphocytic leukemia: A Cancer and Leukemia Group B Study. Blood 69:1441-1449, 1987 (Pubitemid 17085306)
29. Bishop JF, Lowenthal RM, Joshua D, et al: Etoposide in acute nonlymphocytic leukemia: Australian Leukemia Study Group. Blood 75:27-32, 1990 (Pubitemid 20031485)
30. Blaise D, Boiron JM, Faucher C, et al: Reduced intensity conditioning prior to allogeneic stem cell transplantation for patients with acute myeloblastic leukemia as a first-line treatment. Cancer 104:1931-1938, 2005